Funding Round

ONWARD Medical Secures $55M Growth Equity for Spinal Cord Injury Neurostimulation

ONWARD Medical10/20/2025·10/20/25🌐 Europe

Summary

ONWARD Medical raised $55M growth equity for ARC neurostimulation therapies to restore movement, function, and independence after spinal cord injury.

Why it matters

ONWARD Medical's $55M growth equity finances commercialisation of their ARC-EX and ARC-IM spinal cord stimulation platforms following landmark clinical trial results. Their epidural stimulation approach has restored voluntary movement and standing in people with complete spinal cord injury.

#BCI#Neurostimulation#Spinal Cord Injury#Spinal Cord Stimulation

Want the full NeurotechMag Pro intelligence database?

Access 800+ papers, trials, patents, funding rounds and news items — updated daily.

Start free trial

Already a member? Sign in